Prof. Changwen Zhang presented a comprehensive update on the Chinese clinical exploration of ADC-based therapies in urothelial carcinoma. His presentation highlighted the promising role of Vedicitumab (RC48), a HER2-targeted ADC, across multiple disease stages including neoadjuvant treatment for MIBC and bladder-sparing approaches in high-risk NMIBC. Early clinical studies such as TRUCE-04 demonstrated encouraging complete response rates and bladder preservation outcomes, offering new therapeutic possibilities for patients who are ineligible or unfit for standard cisplatin-based chemotherapy. Prof. Zhang also emphasized the importance of biomarker-driven patient selection to refine treatment strategies and improve clinical efficacy.
